Teens with genetic cholesterol disorder tracked for long-term drug safety
NCT ID NCT05682378
Summary
This study follows teenagers with a genetic condition causing very high cholesterol (familial hypercholesterolemia) who previously took the drug inclisiran in earlier trials. The main goal is to monitor the long-term safety and side effects of continued treatment. It also provides these teens continued access to the medication and checks if it keeps their 'bad' cholesterol low over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HETEROZYGOUS OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Childrens Hosp Pittsburgh UPMC
Pittsburgh, Pennsylvania, 15224, United States
-
Cincinnati Childrens Hospital MC
Cincinnati, Ohio, 45229-3039, United States
-
Excel Medical Clinical Trials LLC
Boca Raton, Florida, 33434, United States
-
Icahn School of Med at Mt Sinai
New York, New York, 10029, United States
-
Novartis Investigative Site
Formosa, Formosa Province, P3600, Argentina
-
Novartis Investigative Site
Fortaleza, Ceará, 60430-275, Brazil
-
Novartis Investigative Site
São Paulo, São Paulo, 04023-900, Brazil
-
Novartis Investigative Site
São Paulo, São Paulo, 05403 000, Brazil
-
Novartis Investigative Site
Québec, Quebec, G1V 4W2, Canada
-
Novartis Investigative Site
Prague, 128 08, Czechia
-
Novartis Investigative Site
Prague, 150 06, Czechia
-
Novartis Investigative Site
Besançon, 25030, France
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60590, Germany
-
Novartis Investigative Site
Freiburg im Breisgau, 79100, Germany
-
Novartis Investigative Site
Athens, 115 27, Greece
-
Novartis Investigative Site
Athens, 185 47, Greece
-
Novartis Investigative Site
Pécs, Baranya, 7623, Hungary
-
Novartis Investigative Site
Jerusalem, 9112001, Israel
-
Novartis Investigative Site
Ramat Gan, 5265601, Israel
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Modena, MO, 41124, Italy
-
Novartis Investigative Site
Roma, RM, 00161, Italy
-
Novartis Investigative Site
Roma, RM, 00165, Italy
-
Novartis Investigative Site
Irbid, 22110, Jordan
-
Novartis Investigative Site
Beirut, 113-0236, Lebanon
-
Novartis Investigative Site
Beirut, 166830, Lebanon
-
Novartis Investigative Site
Sungai Buloh, Selangor, 47000, Malaysia
-
Novartis Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Novartis Investigative Site
Amsterdam, North Holland, 1105 AZ, Netherlands
-
Novartis Investigative Site
Rotterdam, South Holland, 3015 GD, Netherlands
-
Novartis Investigative Site
Oslo, 0514, Norway
-
Novartis Investigative Site
Gdansk, 80 952, Poland
-
Novartis Investigative Site
Lodz, Łódź Voivodeship, 93-338, Poland
-
Novartis Investigative Site
Kemerovo, 650002, Russia
-
Novartis Investigative Site
Moscow, 127412, Russia
-
Novartis Investigative Site
Poprad, 058 01, Slovakia
-
Novartis Investigative Site
Ljubljana, 1000, Slovenia
-
Novartis Investigative Site
Bloemfontein, Free State, 9301, South Africa
-
Novartis Investigative Site
Cape Town, Western Cape, 7130, South Africa
-
Novartis Investigative Site
Pamplona, Navarre, 31008, Spain
-
Novartis Investigative Site
Oviedo, Principality of Asturias, 33011, Spain
-
Novartis Investigative Site
A Coruña, 15001, Spain
-
Novartis Investigative Site
Córdoba, 14004, Spain
-
Novartis Investigative Site
Geneva, 1211, Switzerland
-
Novartis Investigative Site
Taipei, 111045, Taiwan
-
Novartis Investigative Site
Istanbul, Fatih, 34098, Turkey (Türkiye)
-
Novartis Investigative Site
Adana, Saricam, 01330, Turkey (Türkiye)
-
Novartis Investigative Site
Ankara, Yenimahalle, 06500, Turkey (Türkiye)
-
Novartis Investigative Site
Izmir, 35100, Turkey (Türkiye)
-
Novartis Investigative Site
Middlesex, UB9 6JH, United Kingdom
-
Primary Childrens Medical Center
Salt Lake City, Utah, 84113, United States
Conditions
Explore the condition pages connected to this study.